DelveInsight has launched a new report on Carcinoid Syndrome Epidemiology
Carcinoid syndrome is the collection of symptoms some people get when a neuroendocrine tumor, usually one that has spread to the liver, releases hormones such as serotonin into the bloodstream. It is predominantly associated with neuroendocrine tumors (NETs) that arise from the mid-gut in the setting of extensive liver metastases but may be present in patients with bronchial carcinoids, and more rarely, in patients with pancreatic NETs.
Request for free sample copy- https://www.delveinsight.com/sample-request/carcinoid-syndrome-epidemiology-forecast
A Carcinoid Syndrome Epidemiology detailed review of historical and forecasted Carcinoid Syndrome market is included in the report, covering drug outreach in the G8 countries.
Carcinoid Syndrome Epidemiology
Carcinoid syndrome refers to a group of symptoms caused by the systemic release of different kinds of humoral factors like polypeptides, biogenic amines, and prostaglandins mostly from well-differentiated neuroendocrine tumors. Previously well-differentiated neuroendocrine tumors were known as carcinoid tumors. Neuroendocrine tumors are derived from enterochromaffin cells that are ubiquitous in our body. As per the study conducted by Alur et al. (2017), it is estimated that only about 10% of neuroendocrine tumors result into carcinoid syndrome. Carcinoid-syndrome is characterized by the presence during the disease at some time of diarrhea, cutaneous flushing, wheezing/asthma-like symptoms, and pellagra-like skin lesions with hyperkeratosis and pigmentation. In Canada, carcinoid tumors represent less than 0.25% of the oncology patient load.
Key facts of the Carcinoid Syndrome Epidemiology report
Carcinoid Syndrome Epidemiology Segmentation
Carcinoid Syndrome Prevalent Population
Carcinoid tumors have a low incidence rate of 1.9 per 100,000. The overall incidence appears to have increased since the early 1970s, which may at least partly reflect better diagnosis and awareness. However, in Ontario, the incidence rose from 2 per million in 1964 to 22 per million in 2002.
What will be the key Questions Answered?
Table of content
1. Key Insights
2. Executive Summary of Carcinoid Syndrome
3. Carcinoid Syndrome: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Reasons to buy
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/